I covered Haw Par Group back in 2019. Hence I think it is time to revisit this company which is trading at multi year lows.
My annual investment review for 2022. This year has been a rollercoaster for the stock market, here are the key takeaways from my portfolio.
We study uniQure NV ($QURE), a biotechnology company focused on developing gene therapies for rare diseases.
VolitionRx is commercially introducing a product with a huge addressable market. If successful, the market will rerate the stock.
uniQure's AMT-061 is currently the world's most expensive drug. Here's why investing in $QURE may be rewarded with strong returns.
Here is my summary and review of "Insider Buy Superstocks". It has some important concepts to achieve great investment returns.
We look at 5 intriguing earnings report I found during this earnings season
Be Boring - How the best investments are the most boring ones. “Investing should be dull. It shouldn't be exciting. Investing should be more like watching paint dry or grass grow. If you want excitement, take $800 and go to Las Vegas” - Paul Samuelson Investing can definitely be exciting. Seeing those numbers tick upwards … Continue reading It Does Pay to Be Boring
Long term investing is not easy. Investors are often excited about the magic of long-term holdings and the ease of multiplying their returns. However, why is it not easy to achieve with such a proven investment strategy?
2020 is the year of COVID-19, a year of uncertainty, and changes happening at a fast pace. It offers several interesting lessons for me. Portfolio Performance My portfolio returned 55.96%. With a bit of luck, I managed to turn it around after that disastrous first half of 2020. At one point I was down 25%. … Continue reading 2020 Review, Lessons Learnt, What I’m looking out for in 2021